Clinical outcomes associated with prostate cancer conspicuity on biparametric and multiparametric MRI: a protocol for a systematic review and meta-analysis of biochemical recurrence following radical prostatectomy. Issue 5 (5th May 2021)

• Record Type: Journal Article
• Authors: Morka, Naomi; Simpson, Benjamin S; Ball, Rhys; Freeman, Alex; Kirkham, Alex; Kelly, Daniel; Whitaker, Hayley C; Emberton, Mark; Norris, Joseph M
• Is Part Of: BMJ open. Volume 11:Issue 5(2021)
• Publication Date: 2021-05-05
• Subjects: urology -- prostate disease -- urological tumours -- magnetic resonance imaging; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-047664
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: There is an increasing body of evidence to suggest that visibility of prostate cancer on magnetic resonance (MRI) may be related to likelihood of adverse pathological outcomes. Biochemical recurrence (BCR) after radical prostatectomy remains a significant clinical challenge and a means of predicting likelihood of this prior to surgery could inform treatment choice. It appears that MRI could be a potential candidate strategy for BCR prediction, and as such, there is a need to review extant literature on the prognostic capability of MRI. Here, we describe a protocol for a systematic review and meta-analysis of the utility of biparametric MRI (bpMRI) and multiparametric MRI (mpMRI) in predicting BCR following radical prostatectomy for prostate cancer treatment. Methods and analysis: PubMed, MEDLINE, Embase and Cochrane databases will be searched and screening will be guided by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. In order to meet the inclusion criteria, papers must be English-language articles involving patients who have had bpMRI or mpMRI for suspected prostate cancer and have undergone radical prostatectomy as definitive therapy. Patients must have had prostate-specific antigen monitoring before and after surgery. All relevant papers published from July 1977 to October 2020 will be eligible for inclusion. The Newcastle-Ottawa score will be used to determine the quality and bias of the studies. This protocol is written in-line with the PRISMA protocol 2015 checklist. Ethics and dissemination: There are no relevant ethical concerns. Dissemination of this protocol will be via peer-reviewed journals as well as national and international conferences. PROSPERO registration number: CRD42020206074.